A Randomized, multicenter, phase II study of cetuximab with docetaxel and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck cancer

Keun Wook Lee, Youngil Koh, Sung Bae Kim, Sang Won Shin, Jin Hyoung Kang, Hong Gyun Wu, Myung Whun Sung, Bhumsuk Keam, Dong Wan Kim, Tae Min Kim, Kwang Hyun Kim, Tack Kyun Kwon, J. Hun Hah, In Ah Kim, Soon Hyun Ahn, Dok Hyun Yoon, Sang Wook Lee, Sang Yoon Kim, Soon Yuhl Nam, Kwang-Yoon Jung & 4 others Seung-Kuk Baek, Sook Hee Hong, Se Hoon Lee, Dae Seog Heo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background. We investigated the efficacy of cetuximab when added to induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) in patients with locally advanced head and neck squamous cell carcinoma. Methods. Patients were randomized to receive three cycles of docetaxel and cisplatin (TP regimen) with or without cetuximab (TP plus cetuximab [CTP] vs. TP) as induction chemotherapy. Patients in the CTP arm received CCRT with cetuximab and cisplatin, whereas patients in the TP arm received cisplatin alone. The primary endpoint was the objective response rate (ORR) after induction chemotherapy. Results. Overall, 92 patients were enrolled. The ORRs for induction chemotherapy in the CTP and TP arms were not different (81% vs. 82%). Adding cetuximab lowered the completion rate of induction chemotherapy and CCRT and resulted in more frequent dose reductions of the induction chemotherapy, although this did not reach statistical significance. In the CTP and TP arms, respectively, the 3-year progression-free survival (PFS) rates were 70% and 56% (p = .359), and the overall survival (OS) rates were 88% and 74% (p = .313). When limited to patients who completed induction chemotherapy, 3-year PFS rates of 78% and 59% (p = .085) and OS rates of 94% and 73% (p = .045) were observed in the CTP and TP arms, respectively. Conclusion. Adding cetuximab to sequential treatment did not increase the treatment efficacy and resulted in greater toxicity. In the intent-to-treat population, neither PFS nor OS was improved by the addition of cetuximab to sequential treatment; however, a suggestion of improved survival outcomes was observed in patients completing cetuximab-containing induction chemotherapy.

Original languageEnglish
Pages (from-to)1119-1120
Number of pages2
JournalOncologist
Volume20
Issue number10
DOIs
Publication statusPublished - 2015 Aug 24

Fingerprint

docetaxel
Induction Chemotherapy
Head and Neck Neoplasms
Cisplatin
Chemoradiotherapy
Survival Rate
Disease-Free Survival
Cetuximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A Randomized, multicenter, phase II study of cetuximab with docetaxel and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck cancer. / Lee, Keun Wook; Koh, Youngil; Kim, Sung Bae; Shin, Sang Won; Kang, Jin Hyoung; Wu, Hong Gyun; Sung, Myung Whun; Keam, Bhumsuk; Kim, Dong Wan; Kim, Tae Min; Kim, Kwang Hyun; Kwon, Tack Kyun; Hun Hah, J.; Kim, In Ah; Ahn, Soon Hyun; Yoon, Dok Hyun; Lee, Sang Wook; Kim, Sang Yoon; Nam, Soon Yuhl; Jung, Kwang-Yoon; Baek, Seung-Kuk; Hong, Sook Hee; Lee, Se Hoon; Heo, Dae Seog.

In: Oncologist, Vol. 20, No. 10, 24.08.2015, p. 1119-1120.

Research output: Contribution to journalArticle

Lee, KW, Koh, Y, Kim, SB, Shin, SW, Kang, JH, Wu, HG, Sung, MW, Keam, B, Kim, DW, Kim, TM, Kim, KH, Kwon, TK, Hun Hah, J, Kim, IA, Ahn, SH, Yoon, DH, Lee, SW, Kim, SY, Nam, SY, Jung, K-Y, Baek, S-K, Hong, SH, Lee, SH & Heo, DS 2015, 'A Randomized, multicenter, phase II study of cetuximab with docetaxel and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck cancer', Oncologist, vol. 20, no. 10, pp. 1119-1120. https://doi.org/10.1634/theoncologist.2015-0208
Lee, Keun Wook ; Koh, Youngil ; Kim, Sung Bae ; Shin, Sang Won ; Kang, Jin Hyoung ; Wu, Hong Gyun ; Sung, Myung Whun ; Keam, Bhumsuk ; Kim, Dong Wan ; Kim, Tae Min ; Kim, Kwang Hyun ; Kwon, Tack Kyun ; Hun Hah, J. ; Kim, In Ah ; Ahn, Soon Hyun ; Yoon, Dok Hyun ; Lee, Sang Wook ; Kim, Sang Yoon ; Nam, Soon Yuhl ; Jung, Kwang-Yoon ; Baek, Seung-Kuk ; Hong, Sook Hee ; Lee, Se Hoon ; Heo, Dae Seog. / A Randomized, multicenter, phase II study of cetuximab with docetaxel and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck cancer. In: Oncologist. 2015 ; Vol. 20, No. 10. pp. 1119-1120.
@article{a025471bf26347708fa3cee2d68e020c,
title = "A Randomized, multicenter, phase II study of cetuximab with docetaxel and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck cancer",
abstract = "Background. We investigated the efficacy of cetuximab when added to induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) in patients with locally advanced head and neck squamous cell carcinoma. Methods. Patients were randomized to receive three cycles of docetaxel and cisplatin (TP regimen) with or without cetuximab (TP plus cetuximab [CTP] vs. TP) as induction chemotherapy. Patients in the CTP arm received CCRT with cetuximab and cisplatin, whereas patients in the TP arm received cisplatin alone. The primary endpoint was the objective response rate (ORR) after induction chemotherapy. Results. Overall, 92 patients were enrolled. The ORRs for induction chemotherapy in the CTP and TP arms were not different (81{\%} vs. 82{\%}). Adding cetuximab lowered the completion rate of induction chemotherapy and CCRT and resulted in more frequent dose reductions of the induction chemotherapy, although this did not reach statistical significance. In the CTP and TP arms, respectively, the 3-year progression-free survival (PFS) rates were 70{\%} and 56{\%} (p = .359), and the overall survival (OS) rates were 88{\%} and 74{\%} (p = .313). When limited to patients who completed induction chemotherapy, 3-year PFS rates of 78{\%} and 59{\%} (p = .085) and OS rates of 94{\%} and 73{\%} (p = .045) were observed in the CTP and TP arms, respectively. Conclusion. Adding cetuximab to sequential treatment did not increase the treatment efficacy and resulted in greater toxicity. In the intent-to-treat population, neither PFS nor OS was improved by the addition of cetuximab to sequential treatment; however, a suggestion of improved survival outcomes was observed in patients completing cetuximab-containing induction chemotherapy.",
author = "Lee, {Keun Wook} and Youngil Koh and Kim, {Sung Bae} and Shin, {Sang Won} and Kang, {Jin Hyoung} and Wu, {Hong Gyun} and Sung, {Myung Whun} and Bhumsuk Keam and Kim, {Dong Wan} and Kim, {Tae Min} and Kim, {Kwang Hyun} and Kwon, {Tack Kyun} and {Hun Hah}, J. and Kim, {In Ah} and Ahn, {Soon Hyun} and Yoon, {Dok Hyun} and Lee, {Sang Wook} and Kim, {Sang Yoon} and Nam, {Soon Yuhl} and Kwang-Yoon Jung and Seung-Kuk Baek and Hong, {Sook Hee} and Lee, {Se Hoon} and Heo, {Dae Seog}",
year = "2015",
month = "8",
day = "24",
doi = "10.1634/theoncologist.2015-0208",
language = "English",
volume = "20",
pages = "1119--1120",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - A Randomized, multicenter, phase II study of cetuximab with docetaxel and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck cancer

AU - Lee, Keun Wook

AU - Koh, Youngil

AU - Kim, Sung Bae

AU - Shin, Sang Won

AU - Kang, Jin Hyoung

AU - Wu, Hong Gyun

AU - Sung, Myung Whun

AU - Keam, Bhumsuk

AU - Kim, Dong Wan

AU - Kim, Tae Min

AU - Kim, Kwang Hyun

AU - Kwon, Tack Kyun

AU - Hun Hah, J.

AU - Kim, In Ah

AU - Ahn, Soon Hyun

AU - Yoon, Dok Hyun

AU - Lee, Sang Wook

AU - Kim, Sang Yoon

AU - Nam, Soon Yuhl

AU - Jung, Kwang-Yoon

AU - Baek, Seung-Kuk

AU - Hong, Sook Hee

AU - Lee, Se Hoon

AU - Heo, Dae Seog

PY - 2015/8/24

Y1 - 2015/8/24

N2 - Background. We investigated the efficacy of cetuximab when added to induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) in patients with locally advanced head and neck squamous cell carcinoma. Methods. Patients were randomized to receive three cycles of docetaxel and cisplatin (TP regimen) with or without cetuximab (TP plus cetuximab [CTP] vs. TP) as induction chemotherapy. Patients in the CTP arm received CCRT with cetuximab and cisplatin, whereas patients in the TP arm received cisplatin alone. The primary endpoint was the objective response rate (ORR) after induction chemotherapy. Results. Overall, 92 patients were enrolled. The ORRs for induction chemotherapy in the CTP and TP arms were not different (81% vs. 82%). Adding cetuximab lowered the completion rate of induction chemotherapy and CCRT and resulted in more frequent dose reductions of the induction chemotherapy, although this did not reach statistical significance. In the CTP and TP arms, respectively, the 3-year progression-free survival (PFS) rates were 70% and 56% (p = .359), and the overall survival (OS) rates were 88% and 74% (p = .313). When limited to patients who completed induction chemotherapy, 3-year PFS rates of 78% and 59% (p = .085) and OS rates of 94% and 73% (p = .045) were observed in the CTP and TP arms, respectively. Conclusion. Adding cetuximab to sequential treatment did not increase the treatment efficacy and resulted in greater toxicity. In the intent-to-treat population, neither PFS nor OS was improved by the addition of cetuximab to sequential treatment; however, a suggestion of improved survival outcomes was observed in patients completing cetuximab-containing induction chemotherapy.

AB - Background. We investigated the efficacy of cetuximab when added to induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) in patients with locally advanced head and neck squamous cell carcinoma. Methods. Patients were randomized to receive three cycles of docetaxel and cisplatin (TP regimen) with or without cetuximab (TP plus cetuximab [CTP] vs. TP) as induction chemotherapy. Patients in the CTP arm received CCRT with cetuximab and cisplatin, whereas patients in the TP arm received cisplatin alone. The primary endpoint was the objective response rate (ORR) after induction chemotherapy. Results. Overall, 92 patients were enrolled. The ORRs for induction chemotherapy in the CTP and TP arms were not different (81% vs. 82%). Adding cetuximab lowered the completion rate of induction chemotherapy and CCRT and resulted in more frequent dose reductions of the induction chemotherapy, although this did not reach statistical significance. In the CTP and TP arms, respectively, the 3-year progression-free survival (PFS) rates were 70% and 56% (p = .359), and the overall survival (OS) rates were 88% and 74% (p = .313). When limited to patients who completed induction chemotherapy, 3-year PFS rates of 78% and 59% (p = .085) and OS rates of 94% and 73% (p = .045) were observed in the CTP and TP arms, respectively. Conclusion. Adding cetuximab to sequential treatment did not increase the treatment efficacy and resulted in greater toxicity. In the intent-to-treat population, neither PFS nor OS was improved by the addition of cetuximab to sequential treatment; however, a suggestion of improved survival outcomes was observed in patients completing cetuximab-containing induction chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84943223014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943223014&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0208

DO - 10.1634/theoncologist.2015-0208

M3 - Article

VL - 20

SP - 1119

EP - 1120

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -